Resultados de búsqueda - Jakob Dupont
- Mostrando 1 - 19 Resultados de 19
-
1
-
2
-
3
-
4
-
5
Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses por Ingo Fricke, Noweeda Mirza, Jakob Dupont, Craig Lockhart, Autumn L. Jackson, Ji‐Hyun Lee, Jeffrey A. Sosman, Dmitry I. Gabrilovich
Publicado 2007Artigo -
6
Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. por Phyllis Speiser, Jakob Dupont, Dongjian Zhu, Joan Serrat, Mimi Buegeleisen, M T Tusié-Luna, Martin Lesser, Maria I. New, Perrin C. White
Publicado 1992Artigo -
7
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors por David C. Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P. Papadopoulos, Min Wang, Ann M. Kapoun, Lu Xu, Jakob Dupont, Robert Stagg, Anthony W. Tolcher
Publicado 2018Artigo -
8
A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors por David C. Smith, Peter D. Eisenberg, Georgy M. Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir I. Šikić
Publicado 2014Artigo -
9
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma por Mario M. Leitão, Robert A. Soslow, Daisuke Nonaka, Adam B. Olshen, Carol Aghajanian, Paul Sabbatini, Jakob Dupont, Martee L. Hensley, Yukio Sonoda, Richard R. Barakat, Sibyl Anderson
Publicado 2004Artigo -
10
Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40 por Jakob Dupont, Meena K. Tanwar, Howard T. Thaler, Martin Fleisher, Noah D. Kauff, Martee L. Hensley, Paul Sabbatini, Sibyl Anderson, Carol Aghajanian, Eric C. Holland, David R. Spriggs
Publicado 2004Artigo -
11
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors por William P. Tew, Michael S. Gordon, John R. Murren, Jakob Dupont, S. Pezzulli, Carol Aghajanian, Paul Sabbatini, David S. Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs
Publicado 2009Artigo -
12
Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma por Paul Sabbatini, Carol Aghajanian, Don S. Dizon, Sybil Anderson, Jakob Dupont, John V. Brown, William A. Peters, Andrew Jacobs, Aminder Mehdi, Saul E. Rivkin, Amy J. Eisenfeld, David R. Spriggs
Publicado 2004Artigo -
13
Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission por Catherine Diefenbach, Sacha Gnjatic, Paul Sabbatini, Carol Aghajanian, Martee L. Hensley, David R. Spriggs, Alexia Iasonos, Helen Lee, Bo Dupont, S. Pezzulli, Achim A. Jungbluth, Lloyd J. Old, Jakob Dupont
Publicado 2008Artigo -
14
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer por Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey A. Douglas, Robert A. Burger, Deborah K. Armstrong, Robert M. Wenham, William P. McGuire
Publicado 2007Artigo -
15
Phase I Study of the Novel Epothilone Analog Ixabepilone (BMS-247550) in Patients With Advanced Solid Tumors and Lymphomas por Carol Aghajanian, Howard A. Burris, Suzanne F. Jones, David R. Spriggs, Marvin B. Cohen, Ronald Peck, Paul Sabbatini, Martee L. Hensley, F. Anthony Greco, Jakob Dupont, Owen A. O’Connor
Publicado 2007Artigo -
16
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas por Xingxing Zang, Peggy Sullivan, Robert A. Soslow, Rebecca Waitz, Victor E. Reuter, Andrew S. Wilton, Howard T. Thaler, Manonmani Arul, Susan F. Slovin, Joyce Wei, David R. Spriggs, Jakob Dupont, James P. Allison
Publicado 2010Artigo -
17
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors por A. Craig Lockhart, Mace L. Rothenberg, Jakob Dupont, Wendy Cooper, Paul Chevalier, Lars Sternås, Giliane Buzenet, Elizabeth Koehler, Jeffrey A. Sosman, Lawrence H. Schwartz, David H. Gültekin, Jason A. Koutcher, Edwin F. Donnelly, Ric Andal, Isabelle Dancy, David R. Spriggs, William P. Tew
Publicado 2009Artigo -
18
Activating <i>NOTCH1</i> Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potent... por Renata Ferrarotto, Yoshitsugu Mitani, Lixia Diao, Irene Guijarro, Jing Wang, Patrick A. Zweidler‐McKay, Diana Bell, William N. William, Bonnie S. Glisson, Michael J. Wick, Ann M. Kapoun, Amita Patnaik, Gail Eckhardt, Pamela N. Münster, Leonardo Faoro, Jakob Dupont, J. Jack Lee, P. Andrew Futreal, Adel K. El‐Naggar, John V. Heymach
Publicado 2017Artigo -
19
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer por Zishuo Ian Hu, Johanna C. Bendell, Andrea J. Bullock, Noelle K. LoConte, Hassan Hatoum, Paul S. Ritch, Hugo Hool, Joseph W. Leach, James F. Sanchez, Davendra Sohal, John H. Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent J. Picozzi, Vaibhav Sahai, Eileen M. O’Reilly
Publicado 2019Artigo
Herramientas de búsqueda:
Materias Relacionadas
Internal medicine
Medicine
Cancer
Biology
Gastroenterology
Oncology
Genetics
Gene
Ovarian cancer
Biochemistry
Breast cancer
Cancer research
Chemotherapy
Hormone
Molecular biology
Pathology
Pharmacokinetics
Pharmacology
Adverse effect
Bevacizumab
Coding region
Exon
Immune system
Immunology
Paleontology
Pharmacodynamics
Stage (stratigraphy)
Steroid
Steroid 11-beta-hydroxylase
Toxicity